Latest Insider Transactions at Enanta Pharmaceuticals Inc (ENTA)
This section provides a real-time view of insider transactions for Enanta Pharmaceuticals Inc (ENTA). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of ENANTA PHARMACEUTICALS INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of ENANTA PHARMACEUTICALS INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 05
2025
|
Kathleen S. Capps Officer |
SELL
Open market or private sale
|
Direct |
323
-3.71%
|
$4,522
$14.23 P/Share
|
|
Dec 05
2025
|
Brendan Luu Chief Business Officer |
SELL
Open market or private sale
|
Direct |
1,394
-3.51%
|
$19,516
$14.23 P/Share
|
|
Dec 05
2025
|
Scott T. Rottinghaus Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
798
-3.53%
|
$11,172
$14.23 P/Share
|
|
Dec 05
2025
|
Harry R. Trout Iii Officer |
SELL
Open market or private sale
|
Direct |
542
-3.21%
|
$7,588
$14.23 P/Share
|
|
Dec 05
2025
|
Jay R. Luly President and CEO |
SELL
Open market or private sale
|
Direct |
4,743
-0.55%
|
$66,402
$14.23 P/Share
|
|
Dec 05
2025
|
Yat Sun Or Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,390
-0.64%
|
$33,460
$14.23 P/Share
|
|
Dec 05
2025
|
Tara Lynn Kieffer Chief Product Strategy Officer |
SELL
Open market or private sale
|
Direct |
2,106
-6.44%
|
$29,484
$14.23 P/Share
|
|
Dec 02
2025
|
Harry R. Trout Iii Officer |
SELL
Open market or private sale
|
Direct |
380
-2.2%
|
$4,940
$13.96 P/Share
|
|
Dec 02
2025
|
Kathleen S. Capps Officer |
SELL
Open market or private sale
|
Direct |
207
-2.32%
|
$2,691
$13.96 P/Share
|
|
Dec 01
2025
|
Harry R. Trout Iii Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
105
-0.6%
|
$1,470
$14.12 P/Share
|
|
Dec 01
2025
|
Kathleen S. Capps Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
85
-0.95%
|
$1,190
$14.12 P/Share
|
|
Dec 01
2025
|
Brendan Luu Chief Business Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
498
-1.24%
|
$6,972
$14.12 P/Share
|
|
Dec 01
2025
|
Yat Sun Or Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
753
-0.2%
|
$10,542
$14.12 P/Share
|
|
Dec 01
2025
|
Tara Lynn Kieffer Chief Product Strategy Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
753
-2.25%
|
$10,542
$14.12 P/Share
|
|
Dec 01
2025
|
Jay R. Luly President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,885
-0.22%
|
$26,390
$14.12 P/Share
|
|
Nov 25
2025
|
Kathleen S. Capps Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,163
+26.02%
|
-
|
|
Nov 25
2025
|
Harry R. Trout Iii Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,463
+27.11%
|
-
|
|
Aug 08
2025
|
Scott T. Rottinghaus Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,217
-8.94%
|
$13,302
$6.99 P/Share
|
|
Feb 12
2025
|
Brendan Luu Chief Business Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,326
-7.64%
|
$16,630
$5.59 P/Share
|
|
Feb 12
2025
|
Brendan Luu Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,500
+14.69%
|
-
|
|
Feb 12
2025
|
Yat Sun Or Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,324
-1.14%
|
$21,620
$5.59 P/Share
|
|
Feb 12
2025
|
Yat Sun Or Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,750
+2.51%
|
-
|
|
Feb 12
2025
|
Scott T. Rottinghaus Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,861
-10.34%
|
$14,305
$5.59 P/Share
|
|
Feb 12
2025
|
Scott T. Rottinghaus Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,750
+26.06%
|
-
|
|
Feb 12
2025
|
Tara Lynn Kieffer Chief Product Strategy Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,326
-9.04%
|
$16,630
$5.59 P/Share
|
|
Feb 12
2025
|
Tara Lynn Kieffer Chief Product Strategy Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,500
+16.93%
|
-
|
|
Feb 12
2025
|
Jay R. Luly President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
7,484
-0.86%
|
$37,420
$5.59 P/Share
|
|
Feb 12
2025
|
Jay R. Luly President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
25,500
+2.84%
|
-
|
|
Feb 12
2025
|
Paul J Mellett Chief Fin. & Admin Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,326
-3.35%
|
$16,630
$5.59 P/Share
|
|
Feb 12
2025
|
Paul J Mellett Chief Fin. & Admin Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,500
+7.03%
|
-
|
|
Feb 12
2025
|
Jay R. Luly President and CEO |
BUY
Open market or private purchase
|
Direct |
45,000
+5.05%
|
$225,000
$5.69 P/Share
|
|
Dec 06
2024
|
Tara Lynn Kieffer Chief Product Strategy Officer |
SELL
Open market or private sale
|
Direct |
2,283
-7.23%
|
$18,264
$8.06 P/Share
|
|
Dec 06
2024
|
Brendan Luu Chief Business Officer |
SELL
Open market or private sale
|
Direct |
2,283
-5.96%
|
$18,264
$8.06 P/Share
|
|
Dec 06
2024
|
Yat Sun Or Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,591
-0.7%
|
$20,728
$8.06 P/Share
|
|
Dec 06
2024
|
Scott T. Rottinghaus Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
866
-4.61%
|
$6,928
$8.06 P/Share
|
|
Dec 06
2024
|
Jay R. Luly President and CEO |
SELL
Open market or private sale
|
Direct |
5,142
-0.64%
|
$41,136
$8.06 P/Share
|
|
Dec 06
2024
|
Paul J Mellett Chief Fin. & Admin Officer |
SELL
Open market or private sale
|
Direct |
2,591
-2.75%
|
$20,728
$8.06 P/Share
|
|
Dec 01
2024
|
Brendan Luu Chief Business Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
753
-1.93%
|
$6,024
$8.6 P/Share
|
|
Dec 01
2024
|
Yat Sun Or Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,595
-0.43%
|
$12,760
$8.6 P/Share
|
|
Dec 01
2024
|
Tara Lynn Kieffer Chief Product Strategy Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
753
-2.33%
|
$6,024
$8.6 P/Share
|
|
Dec 01
2024
|
Paul J Mellett Chief Fin. & Admin Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,595
-1.66%
|
$12,760
$8.6 P/Share
|
|
Dec 01
2024
|
Jay R. Luly President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,829
-0.47%
|
$30,632
$8.6 P/Share
|
|
Aug 08
2024
|
Scott T. Rottinghaus Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,466
-7.24%
|
$17,592
$12.73 P/Share
|
|
Jul 15
2024
|
Scott T. Rottinghaus Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,375
-19.84%
|
$91,375
$17.08 P/Share
|
|
Jul 15
2024
|
Scott T. Rottinghaus Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,375
+16.56%
|
$43,000
$8.99 P/Share
|
|
Jul 12
2024
|
Scott T. Rottinghaus Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,271
-9.47%
|
$34,065
$15.04 P/Share
|
|
Jul 11
2024
|
Scott T. Rottinghaus Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,299
-15.2%
|
$64,485
$15.07 P/Share
|
|
Jun 17
2024
|
Tara Lynn Kieffer Chief Product Strategy Officer |
SELL
Open market or private sale
|
Direct |
7,266
-18.35%
|
$87,192
$12.33 P/Share
|
|
Feb 26
2024
|
Nathaniel S. Gardiner Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,187
+6.41%
|
$41,496
$8.99 P/Share
|
|
Feb 12
2024
|
Tara Lynn Kieffer Chief Product Strategy Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
973
-2.4%
|
$11,676
$12.41 P/Share
|